Ketamine vs. Spravato: Insurance Coverage Guide for Idaho Patients

By Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho

One of the most common questions I receive from patients considering ketamine therapy is: "Will my insurance cover this?"

The answer depends entirely on which ketamine treatment you're asking about — because IV ketamine and Spravato (esketamine nasal spray) have dramatically different insurance coverage profiles. Understanding this distinction before you start treatment can save you thousands of dollars and prevent significant frustration.

This guide is written specifically for patients in Idaho, with attention to the insurance plans most commonly used in our region.

Intravenous (IV) ketamine uses racemic ketamine — the same compound that has been used as an anesthetic for over 50 years. It is administered intravenously in a clinical setting, typically as a series of 6 infusions over 2–3 weeks.

FDA status: IV ketamine is used off-label for depression. It is FDA-approved as an anesthetic, but its use for depression is not an FDA-approved indication.

Insurance coverage: Because IV ketamine is off-label for depression, most insurance plans — including Medicare, Medicaid, and commercial insurers — do not cover it for this indication. Patients typically pay out-of-pocket.

Typical cost in Idaho: $400–$700 per infusion, or $2,400–$4,200 for a standard 6-infusion series. Maintenance infusions (typically monthly or as needed) are an additional ongoing cost.

Spravato is a nasal spray containing esketamine — the S-enantiomer of ketamine. It was developed by Janssen Pharmaceuticals and received FDA approval in March 2019 for treatment-resistant depression (TRD) and in August 2020 for major depressive disorder with acute suicidal ideation or behavior (MDSI).

FDA status: Spravato is FDA-approved for TRD and MDSI — not off-label.

Insurance coverage: Because Spravato is FDA-approved, it is covered by many insurance plans, including Medicare Part B, many commercial insurers, and — with prior authorization — some Medicaid plans.

Administration: Spravato must be administered in a certified healthcare setting under observation for at least 2 hours after each dose. It cannot be taken home. This is a REMS (Risk Evaluation and Mitigation Strategy) requirement due to risks of sedation and dissociation.

Medicare Part B covers Spravato as a physician-administered drug when:

• The patient has a diagnosis of treatment-resistant depression (defined as failure of at least 2 adequate antidepressant trials)
• The drug is administered in a certified healthcare setting
• The patient is monitored for at least 2 hours post-dose

Medicare Part B typically covers 80% of the Medicare-approved amount after the Part B deductible is met. Patients with Medicare supplement (Medigap) plans may have their 20% coinsurance covered as well.

Important: Medicare does not cover Spravato for the MDSI indication under Part B in the same way — coverage rules differ.

Idaho Medicaid (Healthy Connections) covers Spravato with prior authorization for qualifying patients. Coverage criteria typically include:

• Diagnosis of treatment-resistant depression
• Documentation of at least 2 failed adequate antidepressant trials
• Failure of or contraindication to ECT (electroconvulsive therapy)
• Treatment by a qualified prescriber in a certified setting

Idaho Medicaid coverage has expanded in recent years, and we have successfully obtained prior authorization for Medicaid patients at Roth Family Medicine. The process requires thorough documentation but is achievable for qualifying patients.

Coverage for Spravato among commercial insurers in Idaho varies significantly by plan:

Blue Cross of Idaho / Regence BlueShield: Generally covers Spravato with prior authorization. Criteria typically require 2+ failed antidepressant trials and documentation of TRD. Prior authorization approval rates are generally good with adequate documentation.

PacificSource Health Plans: Covers Spravato with prior authorization. Similar criteria to BCBS. We have had good success with prior authorizations for PacificSource patients.

SelectHealth: Covers Spravato with prior authorization. Criteria are similar to other commercial plans.

Aetna: Covers Spravato with prior authorization. Aetna's criteria are generally consistent with FDA labeling.

Cigna: Covers Spravato with prior authorization. Cigna has been generally favorable for Spravato approvals.

United Healthcare: Covers Spravato with prior authorization. UHC criteria are similar to other major commercial plans.

TRICARE: Covers Spravato for active duty and eligible beneficiaries with prior authorization.

For commercial insurance prior authorization, we typically need to document:

1. Confirmed diagnosis of major depressive disorder
2. Adequate trials of at least 2 antidepressants (different classes, adequate dose, adequate duration — typically 6+ weeks)
3. Inadequate response to prior treatments
4. Current PHQ-9 or other validated depression severity score
5. Clinical rationale for Spravato vs. other treatment options

Our team handles the prior authorization process for all Spravato patients. We have extensive experience with the documentation requirements and work proactively to maximize approval rates.

Even with insurance coverage, patients have cost-sharing responsibilities. Here's what to expect:

Deductible: If you haven't met your annual deductible, you'll pay the full cost of Spravato until the deductible is met.

Coinsurance: After the deductible, most plans cover 70–80% of the cost, with the patient responsible for 20–30%.

Copays: Some plans have fixed copays for specialty medications or physician-administered drugs.

Out-of-pocket maximum: Once you reach your plan's out-of-pocket maximum, Spravato is covered at 100% for the remainder of the plan year.

Janssen (the manufacturer of Spravato) offers several programs to reduce patient cost-sharing:

Spravato WithMe: A patient support program that includes copay assistance for commercially insured patients. Eligible patients may pay as little as $10 per treatment session. Income limits and eligibility criteria apply.

Patient Assistance Program: For uninsured or underinsured patients who meet income criteria, Janssen may provide Spravato at no cost.

Our team can help you navigate these programs and determine your eligibility.

For patients who choose IV ketamine — or who are not candidates for Spravato — there are several strategies to manage the out-of-pocket cost:

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs): IV ketamine for depression is a qualified medical expense for HSA and FSA purposes. Using pre-tax dollars can reduce the effective cost by 20–35% depending on your tax bracket.

CareCredit and medical financing: Medical financing options like CareCredit offer interest-free periods that can help spread the cost over time.

Sliding scale fees: Some ketamine providers offer sliding scale fees based on income. We are committed to making ketamine therapy as accessible as possible for our patients — please ask about our pricing options.

Insurance appeals: While coverage for IV ketamine is rare, it is not impossible. Some patients have successfully obtained coverage through appeals, particularly when they can document failure of multiple standard treatments including Spravato. We can provide documentation to support an appeal if appropriate.

The insurance coverage question is important, but it shouldn't be the only factor in your decision. Here's a clinical comparison:

Both IV ketamine and Spravato are effective for treatment-resistant depression. Head-to-head comparison data is limited, but:

• IV ketamine has a larger evidence base and longer clinical track record
• Spravato has FDA approval based on rigorous clinical trials
• Response rates are broadly similar (50–70% for both in TRD populations)
• IV ketamine may produce faster initial response (within hours vs. days)

• IV ketamine: Administered intravenously over 40–60 minutes. Requires IV access. More controlled dosing.
• Spravato: Self-administered nasal spray under observation. No IV required. Must remain in the clinic for 2 hours post-dose.

• IV ketamine: Typically 6 infusions over 2–3 weeks for the initial series, then maintenance as needed
• Spravato: Twice weekly for 4 weeks, then weekly for 4 weeks, then weekly or biweekly for maintenance

• IV ketamine: Typically produces more pronounced dissociative effects. Many patients find the experience meaningful and even therapeutic.
• Spravato: Generally produces milder dissociative effects due to lower bioavailability and different route of administration.

For patients with insurance coverage for Spravato, we generally recommend starting with Spravato — the FDA approval, insurance coverage, and established dosing protocol make it the more accessible option for most patients.

For patients without Spravato coverage, or those who have tried Spravato without adequate response, IV ketamine is an excellent alternative with a strong evidence base.

For patients with acute suicidal ideation, IV ketamine's faster onset may be preferable regardless of insurance coverage.

We individualize every treatment decision based on the patient's clinical situation, preferences, and financial circumstances.

If you're interested in ketamine therapy — IV or Spravato — the first step is a consultation at Roth Family Medicine and Mental Health. We will:

1. Evaluate your diagnosis and treatment history
2. Determine which ketamine treatment is most appropriate for you
3. Verify your insurance benefits for Spravato
4. Handle prior authorization if applicable
5. Discuss self-pay options for IV ketamine if needed
6. Develop a comprehensive treatment plan

We serve patients throughout Southeast Idaho, including Pocatello, Chubbuck, Blackfoot, American Falls, Twin Falls, and the surrounding region.

Book online: ZocDoc Call us: 208-904-4705 Location: 444 Hospital Way, Suite 422, Pocatello, Idaho 83201

Kyle Roth, FNP-BC, APRN, MSN, MHA is a board-certified family nurse practitioner specializing in ketamine therapy, Spravato, and treatment-resistant depression at Roth Family Medicine and Mental Health in Pocatello, Idaho.